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Abstract: Heart failure is one of the major health care issues in the Western world. An increasing number of patients are 
affected, leading to a high rate of hospitalization and high costs. Even with administration of the best available medical 
treatment, mortality remains high. The increase in left ventricular volume after a myocardial infarction is a component of 
the remodeling process. Surgical Ventricular Restoration (SVR) has been introduced as an optional therapeutic strategy to 
reduce left ventricular volume and restore heart geometry. So far, it has been established that SVR improves cardiac 
function, clinical status, and survival in patients with ischemic, dilated cardiomyopathy and heart failure. Since its first 
description , SVR has been refined in an effort to standardize the procedure and to optimize the results. This review will 
discuss the rationale behind surgical reversal of LV remodeling, the SVR technique, its impact on cardiac function and 
survival, and future expectations. 
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INTRODUCTION 
  Heart failure (HF) remains a major public health 
problem. Almost 5 million patients in the United States are 
affected, and 30 to 40% of patients
 die from HF within 1 
year after receiving the diagnosis [1]. The incidence and 
prevalence of heart failure continues to increase due in part 
to an extended average life expectancy and morbidity and 
mortality remain high despite improvement in treatment. HF 
is the leading cause of hospitalization for persons over 65 
years of age, and rates of hospital readmission within 6 
months range from 25% to 50%, resulting in a large 
economic burden [2, 3]. Heart transplantation remains the 
treatment of choice for patients with medically refractory 
end stage HF [4, 5]. However, the need for immunosuppres-
sion and the paucity of donors have greatly restricted the 
selection criteria, leaving many patients and physicians 
seeking other options. Medical therapy, targeted to block the 
neurohormonal pathway, has dramatically improved the 
survival of HF patients by slowing the progression of the 
disease [6-8]. Despite the application of the best available 
medical therapy, the percentage of patients suffering from 
signs and symptoms of HF still remains high. This supports 
the concept that HF progresses independently of neuro-
hormonal activation due to an abnormal and excessive 
increase in left ventricular (LV) volume. This theory, the 
biomechanical model of HF, was first proposed by Mann and 
Bristow [9]. The concept of a biomechanical model of HF 
introduces the need for optional strategies aimed at reducing 
LV volumes, and restoring heart geometry. Surgical 
ventricular restoration (SVR) has been introduced to restore 
LV shape, size, and function in patients with ischemic   
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dilated cardiomyopathy and HF. The technique, initially 
introduced by Dor [10] and Jatene [11], has been refined 
over the last ten years in an effort to standardize the 
procedure and optimize the results. This review will discuss 
the rationale to surgically reverse LV remodeling, the SVR 
technique, its impact on cardiac function and survival, and 
future expectations. 
LV REMODELING 
  Left ventricular remodeling is the process by which 
mechanical, neurohormonal, and possibly genetic factors, 
alter ventricular size, shape, and function. Remodeling 
occurs in several clinical conditions, including myocardial 
infarction (MI), cardiomyopathy, hypertension, and valvular 
heart disease. 
  Myocardial infarcts (MI), particularly large, transmural 
infarcts, result in a number of structural changes involving 
both the infarcted and non-infarcted zones [12]. LV 
remodeling usually begins within the first few hours after an 
MI and may progress over time. Abnormal thinning (called 
“infarct expansion”) and dilatation of the necrotic zone is 
initially considered a compensatory mechanism to maintain 
stroke volume as ejection fraction declines. It is accom-
panied by a secondary volume-overload eccentric 
hypertrophy of the non-infarcted remote regions that should 
counteract the increased wall stress and reduce the stimulus 
for further dilatation [13, 14]. However, a negative balance, 
related to the infarct size and the degree of myocardial cells 
loss, towards LV enlargement may result in loading condi-
tions that promote further dilatation and global ventricular 
dysfunction [12]. Structural and geometric ventricular 
changes proceed along with increased myocyte stress, 
neurohormonal activation, collagen synthesis, fibrosis, and 
remodeling of the extracellular matrix, resulting in further 
deterioration of cardiac function [15].  16    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Di Donato et al. 
SVR RATIONALE 
  SVR has been developed with the goal of improving 
cardiac function through a reduction in LV wall tension in 
accordance with the principle of Laplace’s law. Since LV 
wall tension is directly proportional to the LV internal radius 
and pressure, and inversely proportional to wall thickness, 
any intervention to optimize this relationship would be 
beneficial in terms of improving wall compliance and reduc-
ing filling pressure. Optimization may also be beneficial in 
terms of enhancing the contractile performance of the LV by 
increasing the extent and velocity of systolic fiber shortening 
[16]. 
SVR TECHNIQUE  
  After the first description of the linear suture by Cooley 
in 1958 [17], and the circular external suture described by 
Jatène in 1984 [11], Dor started to use a circular patch to 
reconstruct the LV ("endoventricular circular patch plasty" - 
EVCPP) [10, 18]. This technique, completed during 
cardioplegia, involved opening the ventricle in the center of 
the depressed area and performing a thrombectomy when 
indicated. Then, exclusion of the dyskinetic or akinetic LV 
free wall proceeded with an endoventricular circular suture 
passed through the fibrous tissue above the transitional zone. 
In
 the event of recurrent ventricular arrhythmias, cryotherapy 
was
 applied at the transitional zone. A Dacron patch lined 
with pericardium was secured at the junction of the 
endocardial muscle and scarred tissue, thereby excluding non 
contractile portions of the LV and septum. The excluded scar 
was folded over the patch to assure hemostasis. Myocardial 
revascularization was performed before reconstruction, 
making sure to revascularize the proximal left anterior 
descending segment in addition to performing mitral valve 
repair when indicated. To avoid excessive resection, leaving 
too small a residual volume, Dor introduced the use of an 
intraventricular balloon. The balloon was filled to a volume 
of 60 mL/m
2 for preoperative LVEDV < 150 mL/m
2 or 70 
mL/m
2 for preoperative LVEDV > 150 mL/m
2. It was 
removed before closure of the ventricle. Later, the procedure 
was adopted by many skilled and creative surgeons without 
real standardization, making results difficult to compare. 
McCarthy described a no-patch, double purse-string suture 
technique [19]; Mickleborough described a tailored scar 
excision, with septoplasty when indicated for dyskinetic 
septum, and modified linear closure [20]; Menicanti adopted 
a technique that is similar to the Dor procedure except for the 
use of a pre-shaped mannequin (TRISVR 
TM, Chase Medical 
Richardson, TX), which is illustrated in Fig. (1) [21]. The 
mannequin is useful when the ventricle is not extremely 
enlarged to reduce the risk of the residual cavity being too 
small. It is also useful when the transitional zone between 
scarred and non-scarred tissue is not clearly demarcated, as 
in dilated cardiomyopathy and recent MI.  
  The mannequin is removed before closure of the LV 
cavity, which is done with a direct suture if it is less than 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Upper panel - The mannequin positioned inside the ventricle (Schematic); Lower panels - An image of the mannequin from the 
operating room (left); The circular suture follows the curvature of the mannequin to re-shape the ventricle in an elliptical manner. The patch 
is used to close the ventricular opening (right). Reverse Left Ventricular Remodeling  Current Cardiology Reviews, 2010, Vol. 6, No. 1    17 
cm large, or with an elliptical, synthetic patch if greater than 
3 cm. Regardless, the mannequin is useful in giving the 
surgeon the correct position of the apex and avoiding 
sphericalization of the ventricle. The reconstruction of the 
apex can be difficult when the apical and inferior regions are 
severely dilated. To overcome this difficulty, Menicanti
 
applied a modification of the Dor procedure that involves 
plication of
 the distal inferior wall before patch placement, 
thus placing the apex in a more anterior position as 
illustrated in Fig. (2) [21, 22]. 
  When indicated, the mitral valve is repaired through the 
ventricular opening with a double arm stitch running from 
one trigone to the other, embedding the two arms in the 
posterior annulus of the mitral valve. After that, the suture is 
tied to undersize the mitral orifice [23].  
SVR, CARDIAC FUNCTION AND SURVIVAL 
  The first consistent results using SVR were reported by 
Dor and co-authors. They showed that the procedure 
improves LV function, NYHA functional class, and survival 
by reducing ventricular volumes and increasing the ejection 
fraction (EF). These results were observed not only in 
patients with classic dyskinetic aneurysms, but also in those 
with dilated ischemic cardiomyopathy and severe LV 
dysfunction. [24-26]. More interestingly, our group has 
demonstrated, in a large series of patients (245) treated with 
the Dor procedure, that surgical outcomes relate to the extent 
of LV asynergy and not the type of asynergy (akinetic vs. 
dyskinetic) (the mortality rate ranged between 12.2 % and 
12.5% in large LV aneurysms, vs. 4.8% and 0% in small LV 
aneurysms, with an overall mortality rate of 6.8% reported in 
the first 562 consecutive patients of Dor experience) [27]. A 
few years later the first international registry, the RESTORE 
Group (Reconstructive Endoventricular Surgery, returning 
Torsion
 Original Radius Elliptical shape to the left ventricle), 
confirmed the safety and the efficacy of SVR in 1,198 
patients who underwent the procedure between 1998 and 
2003 [28]. Akinesia was present in 66% of the cases and up 
to 73.3% among patients with LVESV  80ml/m
2. This 
study reported an improvement in EF from
  29.6 ± 11.0% 
preoperatively to 39.5 ± 12.3% postoperatively
 (p < 0.001) 
and a decrease in LVESVI from 80.4 ± 51.4 ml/m
2 
preoperatively
  to 56.6 ± 34.3 ml/m
2 postoperatively (p < 
0.001). Thirty-day mortality after SVR was 5.3%, with this 
value being higher among patients in whom mitral valve 
repair was performed along with SVR (8.7%), versus
 patients 
in whom no mitral valve procedure was required (4.0%,
 p < 
0.001). The overall five-year survival was 68.6 ± 2.8%. After 
five years, 78% of patients were not readmitted to the 
hospital for CHF. Surprisingly, in 2004, Mickleborough 
reported the results from a smaller group of patients (245) 
showing a lower in-hospital mortality rate (2.8%); one, five, 
and ten- year survivals were
  92%, 82%, and 62% [20]. 
However, besides the fact that the technique was different 
from the Dor procedure, it should be pointed out that severe
 
mitral regurgitation (MR) was considered a relative 
contraindication in that study; only six patients (2%) had 
mitral valve surgery. Excellent results have been reported by 
O’Neill and colleagues from the Cleveland Clinic as well 
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Fig. (2). The plication at the inferolateral portion of the ventricle is useful to lift up the new apex. 18    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Di Donato et al. 
[29]. The authors published data obtained from 220 
consecutive patients who underwent SVR. Seventeen percent 
of them had an ICD implanted in situ preoperatively, 49% 
had associated mitral valve surgery, and 7% required an 
intraaortic balloon pump postoperatively. The 30-day 
mortality was 1% and survival at one, three, and five years 
was 92%, 90%, and 80%, respectively. However, the lack of 
the information on the type of asynergy, or on its extension, 
makes these results difficult to compare with those from 
previous series. More recently, our group reported the largest 
single-center study of surgical anterior restoration (1,161 
patients) showing a 30-day cardiac mortality of 4.7% [30]. 
Patients requiring mitral valve repair/replacement (18%) had 
a significantly
  higher (13% vs. 3.0%, p < .001) operative 
mortality rate in agreement with the results from the 
RESTORE. In a subgroup of 254 patients, we reported that 
MR alone does not
 significantly increase operative mortality 
risk. Conversely,
 if associated with NYHA class III/IV, it is 
associated with a significant
 increase in the risk of mortality. 
If severe diastolic
 dysfunction is also present (E/A >2), the 
risk is further increased, demonstrating for the first time, that 
severe diastolic dysfunction may increase the risk of SVR. 
Table 1 shows a summary of the data from the literature. 
SVR and Mitral Regurgitation 
  How and when mitral regurgitation should be corrected 
during SVR, is still a topic of debate. In the failing heart, 
mitral
 regurgitation occurs secondarily to annular dilatation, 
altered
  left ventricular geometry, and papillary muscle 
dysfunction [40, 41]. Volume overload causes progressive 
left ventricular and annular
  dilatation, worsens mitral 
regurgitation, and decreases survival [42, 43].
 It is generally 
Table 1.  Summary of Data from the Literature 
Author (Ref)  Number of Patients  30-Day 
Mortality% 
EF Change 
(Absolute Points) 
% Survival 
   1 Year      2 Years    3 Years    5 Years     10 Years 
Sartipy et al. [31]  101  7.9  27±9 to 33±7 (+6)  88%    79%  65%   
Maxey et al. [32]  95 
(56 with SVR compared 
to 39 CABG alone) 
0  22±11 to 32±9 (+10)    95%       
 Mickleborough et al. 
[20] 
285 2.8  Not  reported  95%      82%  62% 
 Athanasuleas et al. 
[28] 
1198  5.3     29±11 to39±12  
(+10) 
     69%   
Dor et al. [33]  870  7.3  Not reported      na     
 Di Donato/Dor et al. 
[34] 
207 8.1  35±13  to48±12 
(+13) 
98%     82%  
 Cirillo et al. [35]  69  4.3  32±4 to 44±7 
(+12) 
 92%       
 Menicanti et al. [30]   1161  4.7  33±9 to 40±10 (+7)          62%  
 Ribeiro et al. [36]  137   2.6  34±6 to 44±5 
(+10) 
 95%       
Yamaguchi et al. [37]  48  
CABG(†) vs. CABG 
+SVR(‡) 
?  21±6 to 28±7 (†) 
   24±7 to 42±9 (‡) 
 (+18) 
 
 
 
 
 53%  (†) 
90% (‡) 
 
O’Neill et al. [29]  220  1.0  21±7 to 25±9 (+4)  92%    90%  80%   
Conte et al. [38]  78  7.7  23±9 to 29±10 
(+6) 
*pts in NYHA IV 
   68%        
Hernandez et al. [39] 
 STS Registry  
731  9.4  na       na    Reverse Left Ventricular Remodeling  Current Cardiology Reviews, 2010, Vol. 6, No. 1    19 
accepted that moderate to severe MR (grade 3-4+)
  is an 
indication for surgical repair in conjunction with SVR. 
However, it has been reported that adding mitral repair to 
SVR with or without CABG, or to CABG alone, increases 
the operative risk [44-47]. Sartipy and colleagues confirmed 
a higher operative mortality
 (16%) in patients with mild-to-
severe MR undergoing mitral repair
 in conjunction with SVR 
[46]. Overall survival was also significantly
 lower in these 
patients compared with patients undergoing SVR
 without the 
mitral valve procedure. Moreover, in the series by Sartipy, 
the MR was mild (2+) in the majority of patients (18/31). 
  SVR has the potential to improve mitral functioning by 
reducing LV volumes, papillary muscles distances (which is 
a main determinant of functional MR), and rebuilding a more 
normal heart geometry [21, 48, 49]. Recently, our group 
addressed the effectiveness
  of SVR on unrepaired mild 
ischemic
  mitral regurgitation. Our paper showed that SVR 
improves mitral functioning
  by improving geometry 
abnormalities [50]. Overall mid-term survival,
  including 
early mortality, was 93% at 1 year and 88% at 3 years. This 
is higher than would be expected in patients with post-
infarction
  dilated ventricles and depressed left ventricular 
function; suggesting that mitral repair in conjunction with 
SVR may be unnecessary in such patients. A larger popu-
lation and longer follow-up are needed to make the results 
conclusive.  
SVR and Diastolic Function 
  Despite excellent contributions supporting SVR as a 
therapeutic strategy for patients with ischemic HF, few data 
are available on LV diastolic function (DF) in patient 
undergoing SVR. The ventricular remodeling following an 
acute myocardial infarction is accompanied by changes in 
diastolic properties of the LV due to scar formation. This, in 
turn, increases chamber stiffness and compensatory hyper-
trophy of the remote zone, which causes delayed relaxation 
[51]. In turn, the resulting increased filling pressure within 
the ventricle may be responsible for LV dilatation. Experi-
mental studies have suggested surgical volume reduction has 
an adverse effect on DF [52, 53]. Tulner and colleagues 
reported data obtained from pressure-volume loop analysis 
before and after SVR suggesting an improvement in systolic 
function and changes in diastolic properties as evidenced by 
an increased stiffness constant [54]. However, the study was 
conducted under cardioplegia that could be partially 
responsible for interstitial edema and the observed increase 
in diastolic chamber stiffness. This was also suggested by 
Ratcliffe and Guy [55]. Previously, our group reported data 
obtained from invasive simultaneous pressure-volume 
measurements on thirty consecutive patients before and 
approximately 10 days after surgery [56]. We showed an 
improvement in diastolic function after SVR demonstrated 
by a significant increase in the peak filling rate (PFR) and a 
decrease in the constant of pressure decay (Tau). This 
discrepancy with the study of Tulner may be due to different 
time intervals of the postoperative invasive evaluation or to 
the patient profile. In Tulner’s study group, the patients were 
older and 100% were NYHA class III-IV with an EF <30%. 
In contrast, in our study group, the patients were younger 
and 43.3% of them were in NYHA class I-II. Most 
importantly, 63.3% had a dyskinetic scar which is a more 
compliant tissue and its resection or exclu-sion does not 
affect DF that may eventually improve [57].  
  It is reasonable to assume that the geometric impli-
cations, as well as the volume of the residual LV cavity, may 
affect the diastolic function in patients undergoing SVR. We 
addressed this issue in a recent paper [58]. One hundred and 
forty-six patients received a complete echocardiographic 
examination before and after SVR, and at the time of 
discharge (7 to 10 days after surgery). Diastolic function was 
explored using the transmitral flow velocity pattern, and four 
classes were defined: normal, abnormal relaxation, 
pseudonormal, and restrictive pattern. Diastolic function was 
defined as unchanged (no difference in diastolic pattern), 
improved (at least one class less) or worsened (at least one 
class more or, in the case of preoperative restrictive pattern, 
an E/A ratio increase of at least 20%). After SVR, the filling 
pattern was unchanged in 105 cases (72%), improved in 14 
(9.6%), and worsened in 27 (18.4%). Based on univariate 
analysis, the preoperative conicity index (CI, as obtained 
from the apical to short axis ratio in the 4-chamber view, 
Fig. (3) [59] and the end-diastolic volume difference (the 
result of surgical volume reduction) were associated with a 
worse diastolic pattern. This means that globally dilated LV 
cavities (CI < 1) are more likely to worsen the diastolic 
function compared to LV cavities equally dilated but mostly 
at the apical level (CI > 1) due to the presence of a dys-
kinetic scar.  
SVR and LV Dyssynchrony 
  The complex sequence of the events leading to LV 
remodeling involves the presence of electrically unexcitable 
scars. This predisposes the LV to electrical heterogeneity, 
which in turn, induces non-uniform contraction, relaxation, 
and filling with further deterioration of global systolic and 
diastolic function. Cardiac resynchronization therapy (CRT) 
has resulted in enhanced quality of life, improved symptoms, 
and improved survival in patients with refractory heart 
failure due to systolic dysfunction and mechanical 
dyssynchrony as defined by wide QRS [60, 61]. Although 
there is a large amount of data reported in several papers, 
there is still a lot of discussion about this optional therapeutic 
strategy for patients with HF. The reasons are different: - the 
percentage of non-responders (34% in the MIRACLE Trial, 
[62]), whereas there is not a uniform definition of “res-
ponder” or “not responder”; - the lack of standardized 
echocardiographic dyssynchrony parameters for the patient 
selection either for technical or theoretical limitations (myo-
cardial viability within the paced area, underlying myo-
cardial conditions such as fibrosis and hypertrophy, and 
location of the pacing lead) [63]. 
  With an eye to the fact that SVR attempts to exclude the 
scarred tissue, our group reported data from a prospective 
study conducted on thirty patients undergoing SVR at the 
Cardiothoracic Center of Monaco [56]. Patients were 
evaluated using a protocol including simultaneous mea-
surements of ventricular volume and pressure to construct 
pressure/volume and pressure/length loops. Mean QRS 
duration was normal (100 ± 17 msec). We showed that 
intraventricular dyssynchrony and nonuniform contraction 
develop as a consequence of LV remodeling. This was 20    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Di Donato et al. 
independent of electrical conduction delay because no 
patient had left-bundle branch block and preoperative mean 
duration of QRS was <120 ms. We also showed that SVR 
produces a mechanical intraventricular
  resynchronization 
that improves mechanical efficiency and global LV 
performance through an improved synergic distribution of 
regional stress during the isovolumic contraction and 
relaxation phases. Data on the effectiveness of SVR on LV 
dyssynchrony have been confirmed by other studies [54, 64]. 
SVR and Arrhythmias 
  The increased risk for life-threatening arrhythmias after a 
myocardial infarction is related to the complex sequence of 
events leading to LV remodeling. These events include LV 
dilatation, which, in turns, increases wall stress and stretch 
(stretch is arrhythmogenic per sè), and to the presence of 
electrically unexcitable scars. Our group has previously 
demonstrated that patients with ventricular arrhythmias 
(spontaneous or inducible) have end-diastolic and end-
systolic volumes significantly larger than those seen in non-
inducible patients [65, 66]. SVR has the potential to reduce 
ventricular arrhythmias by excluding the scar, reducing 
volumes and thus intraventricular stress and stretch. Ventri-
cular arrhythmias are further reduced by relieving ischemia 
through complete revascularization and improving mecha-
nical resynchronization. So far, different groups have 
reported a marked reduction of inducible arrhythmias and a 
very low incidence of sudden death after SVR [20, 65-67]. 
This may limit the need for ICD implantation in patients who 
undergo SVR. The only “negative” contribution, which in 
fact is not absolutely negative in the “ICD era”, has been 
reported by O’Neill and co-workers from the Cleveland 
Clinic. Their report showed that after SVR for ischemic 
cardiomyopathy, either akinetic or dyskinetic, patients may 
remain at risk for malignant ventricular arrhythmias and may 
benefit from prophylactic ICD implantation [68]. Those 
authors reported a high residual incidence of inducible VT 
after surgery (42%) and they implanted an ICD in almost 
50% of cases in their series. They asserted that ICD 
implantation may have saved 15 lives because there were 15 
appropriate ICD firings. However, the Madit II Trial con-
cluded that an appropriate firing of an ICD identifies patients 
at increased risk for subsequent heart failure and non sudden 
cardiac death [69]. Several limitations, including the 
question-able validity of an EP study as a risk stratifier 
(different protocol of programmed ventricular stimulation, 
contraindication to be performed in patients with intra-
ventricular thrombi, left main disease and/or extremely 
severe LV dysfunction) and the use of different techniques, 
support the need for caution in interpreting those results. 
SVR and Myocyte Stress 
  Brain natriuretic peptide (BNP) and its precursor, N-
terminal pro-brain natriuretic peptide (NT-pro-BNP), are 
synthesized in the myocytes and released during hemody-
namic stress. This stress occurs when ventricles are dilated, 
hypertrophic, or subject to increased wall tension [70]. The 
prohormone is then cleaved by a circulating endoprotease. 
BNP causes arterial vasodilation, diuresis, and natriuresis, 
and reduces the activities of the renin-angiotensin–aldos-
terone system and the sympathetic nervous system in an 
effort to balance the physiologic abnormalities in heart 
failure [15]. 
  Previous studies have demonstrated that BNP is a 
valuable biomarker for LV remodeling as its activation is 
more pronounced in patients with functional MR rather that 
in those with organic MR, and it may predict mortality and 
morbidity in patients with chronic HF [71-74]. Using this 
relationship, changes in BNP and NT-pro-BNP levels over 
time could be used to monitor surgical strategies aimed at 
reversing LV remodeling. The first report addressing this 
topic was published by Schenk and colleagues from the 
Cleveland Clinic Foundation [75]. Those authors showed a 
decrease in plasma levels of BNP by 46% from baseline 
(before SVR) to 3 months postoperatively. More recently, 
Sartipy and colleagues reported a similar trend in changes of 
B-type natriuretic peptides after SVR [76]. Specifically, NT-
 
 
 
 
 
 
 
 
 
 
Fig. (3). An example of classic aneurysm showing an apical axis that is bigger than the short axis (systolic CI=1.15) (left). An example of 
ischemic dilated cardiomyopathy showing an apical axis that is smaller than the short axis (systolic CI= 0.72) (right). Reverse Left Ventricular Remodeling  Current Cardiology Reviews, 2010, Vol. 6, No. 1    21 
pro-BNP was significantly reduced by 37% and 51% 6 
months after surgery and at late follow-up, respectively (p = 
0.03). A similar reduction was observed for BNP levels at 
the same time-points (by 20% and 34%, respectively), 
although this reduction was not statistically significant. 
NYHA improvement correlated significantly with a 
reduction in BNP and NT-pro-BNP levels 6 months after 
SVR (r = 0.61 and r = 0.58, respectively), with an increase in 
ejection fraction (r = - 0.58 and r = - 0.51, respectively) and 
with a decreased LV end-systolic volume (r = 0.65 and r = 
0.62, respectively). Larger studies and longer follow-ups are 
required to investigate if reduced levels of natriuretic 
peptides after SVR are associated with better long-term 
survival. 
CRITICISMS AND FUTURE EXPECTATIONS 
  To date, the data  reported in the literature  support the 
benefit of SVR in improving cardiac function and survival in 
patients with dilated ischemic cardiomyopathy and heart 
failure. However, the limitations of different studies are still 
considerable and make the results presently inconclusive. 
First, the majority of studies are retrospective and are not 
powered to address specific end-points either for the number 
of patients, the limited number of events, or for the length of 
the follow-up. Second, physiologic studies based on invasive 
measurements (pressure-volume relationships) have been 
conducted only on small series of patients. Also, the posto-
perative measurements were made immediately after the 
completion of the surgical procedure, or at most, ten days 
after surgery. Additional information will be provided from 
these studies performed at later time points. Third, the lack 
of a control group is one of the major limitations of these 
studies, and the combination of SVR and coronary artery 
bypass surgery in the majority of the study groups does not 
allow for evaluation of the specific role of each procedure. 
Fourth, different surgical techniques and operative protocol 
must be taken in account in interpreting the results. 
  The STICH Trial (Surgical Treatment for Ischemic Heart 
Failure), sponsored by the National Institutes of Health, is a 
multicenter, international, randomized trial designed to 
assess the potential superiority of CABG over intensive 
medical therapy in improving long-term survival (“the 
revascularization hypothesis”). It also assesses the benefit of 
surgical ventricular restoration combined with CABG in 
improving survival free of hospitalization for cardiac cause 
compared to CABG alone in patients with LV dysfunction ( 
EF < 35%) and coronary artery disease suitable for surgical 
revascularization (“the reconstruction hypothesis”). Patients 
will undergo cardiac magnetic resonance imaging, echocar-
diography, neurohormonal and genetic profile, and radio-
nuclide studies to ensure consistent testing practices and 
standardization of data collection. Testing will also identify 
eligible patients and address specific questions related to the 
primary hypotheses. Until the results of this study are 
available, a close collaboration between cardio-logists and 
cardiac surgeons in patient selection, perioperative mana-
gement, and long-term follow-up is critical to definitively 
change the clinical decision making in the treatment of 
ischemic heart failure. 
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